IDH2 and central nervous system cancer: Although a recent clinical trial reported that an inhibitor targeting mutant IDH1 and IDH2 induced durable therapeutic efficacy in lowgrade glioma [24], the impact of directly targeting mutant IDH for high-grade glioma is under clinical investigation.